Organic compounds -- part of the class 532-570 series – Organic compounds – Cyclopentanohydrophenanthrene ring system containing
Reexamination Certificate
2002-06-05
2004-02-17
Badio, Barbara P. (Department: 1616)
Organic compounds -- part of the class 532-570 series
Organic compounds
Cyclopentanohydrophenanthrene ring system containing
C514S182000
Reexamination Certificate
active
06693207
ABSTRACT:
BACKGROUND OF THE INVENTION
The use of naturally occurring estrogenic compositions of substantial purity and low toxicity such as PREMARIN (conjugated equine estrogens) has become a preferred medical treatment for alleviating the symptoms of menopausal syndrome, osteoporosis/osteopenia in estrogen deficient women and in other hormone related disorders. The estrogenic components of the naturally occurring estrogenic compositions have been generally identified as sulfate esters of estrone, equilin, equilenin, 17-&bgr;-estradiol, dihydroequilenin and 17-&bgr;-dihydroequilenin (U.S. Pat. No. 2,834,712). The estrogenic compositions are usually buffered or stabilized with alkali metal salts of organic or inorganic acids at a substantially neutral pH of about 6.5 to 7.5. Urea has also been used as a stabilizer (U.S. Pat. No. 3,608,077). The incorporation of antioxidants to stabilize synthetic conjugated estrogens and the failure of pH control with tris(hydroxymethyl)aminomethane (TRIS) to prevent hydrolysis is discussed in U.S. Pat. No. 4,154,820.
One of the compounds described herein, 5,7,9-estratriene-3&bgr;,17&bgr;-diol 3-sulfate ester sodium salt is a minor component of PREMARIN (conjugated equine estrogens).
REFERENCES:
patent: 2834712 (1958-05-01), Beall et al.
patent: 3608077 (1971-09-01), Ginsig
patent: 4154820 (1979-05-01), Simoons
patent: 635781 (1936-10-01), None
patent: 864231 (1961-03-01), None
Physicians′ Desk Reference, 48thedition, pp. 2594-2596, 1994.*
Renaud, Serge, Atherosclerosis, vol. 12(3), pp. 467-473, 1970.*
Pick et al., Progr. Biochem. Pharmacol., vol. 4, apges 354-362, 1968.*
Johnson, R. et al., J. Pharmac Sci., 67(9), Sep. 1978, pp. 1218-1224.
Starka, L. et al., J. Eur. Steroides, 1(1), 1966, pp. 37-45.
Bachman, W.E. et al., Helv. Chimica Acta., 42(6), Oct. 15, 1959, pp. 1790-1793.
Eimasry, A.H. et al., J. Pharmac. Sci., 59(4), Apr. 1970, pp. 449-458.
Kocovsky, P. et al., Collect. of Czech. Chemical Commun., 39(7), 1974, p. 1909.
Schuller, W.H. et al., J. Med. Chem., 14(5), May 1971, p. 466.
Peters, R.H. et al., J. Med. Chem., 32(7), Jul. 1989, pp. 1642-1652.
Physician Desk Reference, 48thEdition, pp. 2594-2596, 1994.
Goodman and Gilman, seventh edition, pp. 1420-1423, 1985.
Starka et al., J. Eur. Steroids, 1(1), pp. 37-45, 1966.
Banerjee et al., Indian J. Chem., vol. 7, pp. 529-532, 1969.
Kagan Michael Z.
Raveendranath Panolil
Shah Syed M.
Winkley Michael W.
Badio Barbara P.
Milowsky Arnold S.
O'Connor, Esq. Cozen
Wyeth
LandOfFree
B-ring estratriene diols does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with B-ring estratriene diols, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and B-ring estratriene diols will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3285263